11/27/21, 7:00 AM RePORT ) RePORTER

Back to Search Results

**Description** 





**Publications** 

**Patents** 

**Outcomes** 

**Clinical Studies** 

News and More

(L) History

**Similar Projects** 

## **Biodefense and Emerging Infectious Disease Monoclonal Antibody Studies**

Project Number Contact PI/Project Leader 1ZIAAI005139-01 LEDGERWOOD, JULIE

Awardee Organization NATIONAL INSTITUTE OF

ALLERGY AND INFECTIOUS DISEASES



#### **Abstract Text**

Infectious Diseases research project is aimed at the clinical evaluation of monoclonal antibody (mAb) products related to infectious disease pathogens. Current targets include Ebola virus disease and malaria. Further evaluation will continue as the VRC develops additional monoclonal anitbody products aimed at emerging infectious disease targets. Published results from clinical trials include: Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibodymAb114targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C, Vazquez S, Laurencot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT, McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ, Ledgerwood JE; VRC 608 Study team. Lancet. 2019 Mar 2;393(10174):889-898.

#### **Public Health Relevance Statement**

Data not available.

## **NIH Spending Category**

Biodefense Biotechnology Clinical Research

Infectious Diseases Orphan Drug Rare Diseases Vaccine Related

## **Project Terms**

**Clinical Trials Ebola Hemorrhagic Fever Communicable Diseases Drug Kinetics Ebola virus Emerging Communicable Diseases Glycoproteins Evaluation Monoclonal Antibodies Infectious Diseases Research Publishing** Malaria Safety **Research Project Grants Therapeutic Vaccine Research** Virus open label biodefense immunogenicity novel strategies pathogen

phase 1 study programs research clinical testing

# **Details**

Title

Contact PI/ Project Other PIs Program Official

Leader Not Applicable Name

Name Contact <u>LEDGERWOOD, JULIE</u> ✓ Email not available

Thank you for your feedback!

RePORT ) RePORTER 11/27/21, 7:00 AM

Back to Search Results

**Description** 



**Details** 



**Sub-Projects** 





**Patents** 

**Outcomes** 



**Clinical Studies** 

**News and More** 



<u>History</u>



**Similar Projects** 

## **Biodefense and Emerging Infectious Disease Monoclonal Antibody Studies**

**Project Number** 1ZIAAI005139-01 **Contact PI/Project Leader** LEDGERWOOD, JULIE

**Awardee Organization NATIONAL INSTITUTE OF ALLERGY AND** 

**INFECTIOUS DISEASES** 

**DISEASES** City

Country

**Organization Type** Unavailable

Congressional District

### **Other Information**

**ALLERGY AND INFECTIOUS** 

FOA

**Study Section** 

Fiscal Year 2019

Administering Institutes or

Centers

**NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES** 

**DUNS Number CFDA Code** 

**Project Start** 

Date

**Project End** 

Date

**Budget Start** 

Date

**Budget End** Date

## **Project Funding Information for 2019**

**Award Notice** 

Date

**Total Funding** \$2,481,382

**Direct Costs** \$0

**Indirect Costs** 

\$0

Year

**Funding IC** 

2019 NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

\$2,481,382

## **NIH Categorical Spending**

## **Click here for more information on NIH Categorical Spending**

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$2,357,313	Biodefense
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$2,481,382	Biotechnology; Clinical Research; Clinical Trials and Supportive Activities; Emerging Infectious Diseases; Immunization; Infectious Diseases; Orphan Drug; Rare Diseases; Vaccine Related;

品 Sub Projects

No Sub Projects information available for 1ZIAAI005139-01



Thank you for your feedback!

RePORT ) RePORTER 11/27/21, 7:00 AM

Back to Search Results

**Description** 

**Details** 

Sub-Projects

**Publications** 

**Patents** 

Outcomes

**Clinical Studies** 

**News and More** 

<u>History</u>

**Similar Projects** 

## **Biodefense and Emerging Infectious Disease Monoclonal Antibody Studies**

**Project Number** 1ZIAAI005139-01

**Contact PI/Project Leader** LEDGERWOOD, JULIE

**Awardee Organization NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES** 

VIEW AII

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.

The New England journal of medicine 2019 12 12; 381 (24) 2293-2303

Mulangu, Sabue: Dodd. 2019

M G

G

**iCite** 81.71

View All

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.

Lancet (London, England) 2019 03 Gaudinski, 02; 393 (10174) 889-898

Martin R:

2019

M G

<u>iii</u> G

**iCite** 5.50

View All



## **Patents**

No Patents information available for 1ZIAAI005139-01

### **Outcomes**

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 1ZIAAI005139-01

## **Clinical Studies**

No Clinical Studies information available for 1ZIAAI005139-01

### **News and More**

### Related News Releases

No news release information available for 1ZIAAI005139-01

## History

No Historical information available for 1ZIAAI005139-01



11/27/21, 7:00 AM RePORT ) RePORTER

**∢** Back to Search Results

## **Biodefense and Emerging Infectious Disease Monoclonal Antibody Studies**

**Description** 

**Details** 

Sub-Projects

**Publications** 

**Patents** 

**Outcomes** 

**Clinical Studies** 

**News and More** 

<u>History</u>

Similar Projects

**Project Number** LEDGERWOOD, JULIE 1ZIAAI005139-01

**Contact PI/Project Leader** 

**Awardee Organization** NATIONAL INSTITUTE OF **ALLERGY AND INFECTIOUS DISEASES**